# Cellbricks Therapeutics ## Posts - [Cellbricks Therapeutics Raises €10 Million New Capital to Move Living Tissue Implants Toward the Clinic​](https://cellbricks-therapeutics.com/cellbricks-therapeutics-raises-e10-million-new-capital-to-move-living-tissue-implants-toward-the-clinic/): Press release | - [PitchBook Lists Cellbricks Among the Most Promising Biofabrication Companies Worldwide](https://cellbricks-therapeutics.com/pitchbooks-2025-emerging-space-brief-on-bioprinting-lists-cellbricks-among-the-most-promising-companies-worldwide/): Feature | PitchBook | - [Startup of the Week: Cellbricks - 3D Bioprinting Human Tissue | (Gründer*in der Woche: Cellbricks - menschliches Gewebe per 3D-Druck)](https://cellbricks-therapeutics.com/startup-of-the-week-cellbricks-3d-bioprinting-human-tissue-gruenderin-der-woche-cellbricks-menschliches-gewebe-per-3d-druck/): Feature | StartingUp | - [Germany’s Economic Crisis: How Future Business Models Could Look Like | (Wirtschaft in der Krise: Braucht Deutschland ein neues Geschäftsmodell?)](https://cellbricks-therapeutics.com/wirtschaft-in-der-krise-braucht-deutschland-ein-neues-geschaeftsmodell/): Feature | ZDF | - [Former BioNTech CFO, Michael Kring, Joins Cellbricks as Chief Financial Officer](https://cellbricks-therapeutics.com/former-biontech-cfo-michael-kring-joins-cellbricks-as-chief-financial-officer/): Press release | - [Former J&J and Novartis Executive, Dr. Kathy Kordy, M.D. Joins Cellbricks as Chief Medical Officer](https://cellbricks-therapeutics.com/former-biontech-cfo-michael-kring-joins-cellbricks-as-chief-financial-officer-2/): Press release | - [3D-Bioprinted Organ Tissue: Startup Announces Successful Animal Trials | (Organe aus dem 3D-Drucker – Start-up meldet Erfolg in Tierversuchen)](https://cellbricks-therapeutics.com/michael-kring-cfo/): Feature | Handelsblatt | - [Breakthrough in 3D-Bioprinted Tissue and Organ Technology Following Positive Animal Trials](https://cellbricks-therapeutics.com/press-release-april-25/): Press release | - [Cellbricks Therapeutics Expands to the U.S., Launches Subsidiary in Cambridge, MA](https://cellbricks-therapeutics.com/cellbricks-therapeutics-expands-to-the-u-s-launches-subsidiary-in-cambridge-ma/): Feature | Business of Biofabrication - [From Handheld X-rays to 3D Printing of Human Tissue, These Health Innovations Could Change Your Life](https://cellbricks-therapeutics.com/from-handheld-x-rays-to-3d-printing-of-human-tissue-these-health-innovations-could-change-your-life/): Feature | Fast Company | - [McKinsey & Handelsblatt Select Cellbricks as Spark Award Winner Among 750 MedTech Start-ups](https://cellbricks-therapeutics.com/mckinsey-and-handelsblatt-select-cellbricks-as-spark-award-winner-among-750-medtech-start-ups/): Feature | McKinsey | ## Pages - [Cookie-Richtlinie (EU)](https://cellbricks-therapeutics.com/cookie-richtlinie-eu/) - [Legal notice / imprint](https://cellbricks-therapeutics.com/legal-notice-imprint/): Legal notice / imprint Angaben gemäß § 5 TMG:  Cellbricks GmbH, Müllerstrasse 178, 13353 Berlin Vertreten durch: Alexander Leutner, Müllerstrasse 178, 13353 Berlin Kontakt: Telefon: +49 30 5771 2530, E-Mail: info[at]cellbricks.com Registergericht: Amtsgericht Charlottenburg (Berlin)Registernummer: HRB 179568 B eRecht24 Haftungsausschluss (Disclaimer) Haftung für Inhalte Als Diensteanbieter sind wir gemäß § 7 Abs.1 TMG für eigene Inhalte auf diesen Seiten nach den allgemeinen Gesetzen verantwortlich. Nach §§ 8 bis 10 TMG sind wir als Diensteanbieter jedoch nicht verpflichtet, übermittelte oder gespeicherte fremde Informationen zu überwachen oder nach Umständen zu forschen, die auf eine rechtswidrige Tätigkeit hinweisen. Verpflichtungen zur Entfernung oder Sperrung der Nutzung […] - [Privacy policy](https://cellbricks-therapeutics.com/privacy-policy-2/): Privacy policy Die Betreiber dieser Seiten nehmen den Schutz Ihrer persönlichen Daten sehr ernst. Wir behandeln Ihre personenbezogenen Daten vertraulich und entsprechend der gesetzlichen Datenschutzvorschriften sowie dieser Datenschutzerklärung.Die Nutzung unserer Webseite ist in der Regel ohne Angabe personenbezogener Daten möglich. Soweit auf unseren Seiten personenbezogene Daten (beispielsweise Name, Anschrift oder E-Mail-Adressen) erhoben werden, erfolgt dies, soweit möglich, stets auf freiwilliger Basis. Diese Daten werden ohne Ihre ausdrückliche Zustimmung nicht an Dritte weitergegeben.Wir weisen darauf hin, dass die Datenübertragung im Internet (z.B. bei der Kommunikation per E-Mail) Sicherheitslücken aufweisen kann. Ein lückenloser Schutz der Daten vor dem Zugriff durch Dritte ist […] - [Entire Team](https://cellbricks-therapeutics.com/entire-team/): Team We are an interdisciplinary team of biotechnologists, engineers, chemists, and entrepreneurs from over 14 nations, driven by excellence and a proactive spirit. With every team member, we add more passion and expertise to our mission. Linkedin-in Dr. Enrico Accastelli Innovation & Prototype Scientist Linkedin-in Jonas BlomeResearch Assistant Linkedin-in Aramis BolañosSenior Tissue Engineer Linkedin-in Dr. Laura ElomaaSenior Tissue Engineer Linkedin-in Devon ForsytheTechnical Assistant Linkedin-in Lena GrebenchukJunior Tissue Engineer Linkedin-in Chris HegartyOperations Manager Associate Linkedin-in Dr. Kathy Kordy, MD Chief Medical Officer  Linkedin-in Michael KringCFO  Linkedin-in Dr. Tobias LamCTO & Co-founder Linkedin-in Dr. Yannis Lazis Junior Tissue Engineer Linkedin-in Lukas LeimkühlerLead Engineer Linkedin-in Alexander […] - [About us](https://cellbricks-therapeutics.com/about-us/): About Us Cellbricks Therapeutics is a Berlin and Boston-based preclinical biotech company pioneering the future of regenerative medicine and longevity. Built on deep tech innovation, the company combines proprietary biofabrication technology with advanced biomaterials and human cells to develop implantable tissue grafts for clinical use. Cellbricks’ mission is to transform healthcare by restoring tissue function – reliably and at scale. Team Our team unites deep scientific, clinical and business expertise to bring life-saving tissue therapeutics into the clinic – backed by over 100 years of tissue engineering experience. Leadership Linkedin-in Alexander LeutnerCo-CEO (Business) & Co-founder Formerly founded, scaled & successfully […] - [News](https://cellbricks-therapeutics.com/news/): News Trusted media sources are sharing our journey. Find the latest company press releases and features below. Featured in - [Team](https://cellbricks-therapeutics.com/team/): Team Our team unites deep scientific, clinical and business expertise to bring life-saving tissue therapeutics into the clinic backed, by 100 years of tissue engineering experience. Management Alexander Leutner Linkedin-in CO-CEO (Business) & Co-founder Formerly founded, scaled & successfully exited deep-tech start-up to Hexagon. 12 years building and leading teams in start-up and corporate settings. Dr. Simon MacKenzie Linkedin-in CO-CEO (Therapeutic Programs) Former CEO at RegenHU; CBO at Axol Bioscience; Director at Kyorin Pharmaceutical Co. 25 years leading biotech & pharma therapeutics teams across US, EU, Asia. Dr. Kathy Kordy, MD Linkedin-in Chief Medical Officer Former Head of Rare Disease […] - [Therapeutic Programs](https://cellbricks-therapeutics.com/pipeline/): Therapeutic Programs We are advancing two therapeutic programs addressing millions of patients with severe and life-limiting conditions. Staging for success: Our technology will be validated efficiently in the clinic – initially with soft tissue therapeutics for wounds. Our second program is liver tissue aiming to restore liver function. Soft Tissue Therapeutics filling and healing of deep complex wounds Liver Tissue Therapeutics restore liver function in chronic liver disease  Soft Tissue Therapeutic filling and healing of deep complex wounds Liver Tissue Therapeutic restore liver function in chronic liver disease  Development Pipeline - [Technology](https://cellbricks-therapeutics.com/technology/): Technology Cellbricks‘ proprietary light-based biofabrication system introduces a novel and automated approach to producing human tissue therapeutics – enabling scalability and speed beyond other methods – supported by AI-powered tissue engineering.  Step 1: Material Loading Therapeutic cells + customized biomaterials loaded into biofabrication system. Step 2: Tissue Production Biofabrication technology, enhanced by AI-powered tissue engineering, combines cells and biomaterials into human tissue. Step 3: Functional Tissue Within minutes immune-compatible, biological functional tissue therapeutics are produced. Step 4: Function Recovery Application of tissue therapeutics to the patient to restore soft tissue defects or organ function. Key Advantages Our technology meets all […] - [Home](https://cellbricks-therapeutics.com/): The Future of Medicine: Human Tissue Therapeutics A tissue therapeutics company – built on DeepTech innovation – offering a scalable solution to restore lost tissue and organ function for millions of patients. Light-based biofabricated tissue therapeutic The Problem Tissue Dysfunction Every 30 seconds, a patient dies from a disease caused by tissue dysfunction. After decades of research, we still lack reliable solutions to restore lost cell and organ function. Injectable cell therapies underdeliver due to limited cell retention and organ transplantation is highly limited.  The Solution Tissue Therapeutics We develop advanced, cell-based human tissue therapeutics to treat conditions with no […] [comment]: # (Generated by Hostinger Tools Plugin)